Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) reported inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved stock options for ten new non-executive employees under the 2021 Inducement Plan.
The options cover an aggregate 698,000 shares, are priced at fair market value on the grant date, and vest over four years, with 25% after one year and the remainder quarterly, subject to possible acceleration or forfeiture.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
IRD gained 1.22% while biotech peers were mixed: IMUX, OVID and ATRA rose, OKYO fell and ANEB was flat. The momentum scanner did not flag a coordinated sector move, suggesting today’s action is more company-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 13 | Conference presentation | Positive | -2.9% | Announced upcoming RBC healthcare conference presentation and webcast access. |
| May 12 | Earnings and update | Positive | +1.2% | Reported Q1 2026 results, financing steps and broad pipeline progress. |
| May 07 | ARVO data update | Positive | -6.9% | Presented ARVO data showing functional gains in multiple IRD programs. |
| May 07 | Clinical enrollment | Positive | +1.9% | Completed Cohort 1 enrollment in Phase 1/2 OPGx‑BEST1 gene therapy trial. |
| May 04 | FDA program acceptance | Positive | -0.4% | FDA accepted OPGx‑LCA5 into the Rare Disease Evidence Principles program. |
Recent news has been largely positive, yet price reactions were mixed, with several constructive clinical and regulatory updates followed by downside moves, indicating investors have not consistently rewarded good news.
Over the last month, Opus reported multiple milestones, including FDA RDEP acceptance for OPGx‑LCA5 on May 4, Phase 1/2 OPGx‑BEST1 Cohort 1 enrollment completion on May 7, and ARVO 2026 data showing functional gains across programs. Q1 2026 results on May 12 highlighted higher losses but a strengthened cash position and funding runway. A conference presentation was announced for May 19. Today’s inducement grants align with this growth phase, reflecting ongoing hiring to support pipeline execution.
Regulatory & Risk Context
An effective S-3/A registration filed on 2026-04-20 covers resale of up to 7,374,632 shares of common stock issuable upon conversion of Series B Non‑Voting Convertible Preferred Stock. The company will not receive proceeds from these resales, which instead go to selling stockholders. Shares outstanding were 71,402,472 as of March 31, 2026.
Market Pulse Summary
This announcement details inducement option grants for 698,000 shares to ten new non-executive employees under Nasdaq Listing Rule 5635(c)(4). The options vest over 4 years, aligning retention with long-term pipeline execution. Against a backdrop of recent clinical progress and strengthened financing, the grants underline Opus’s hiring and growth phase. Investors may watch how overall equity compensation and the registered resale of 7,374,632 shares interact with future capital needs and share count.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
exercise price financial
fair market value financial
vesting financial
AI-generated analysis. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to ten non-executive employees who were not previously employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted in the form of options to purchase an aggregate of 698,000 shares of the Company’s common stock. The option awards have an exercise price equal to the fair market value of an underlying share of Company common stock as of the grant date and vest over a period of four years, with
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Contacts
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
